Kugwirizana kwatsopano kwachipatala pochiza khansa ya prostate

Clarity Pharmaceuticals adalengeza kuti kuyesa koyambitsa ofufuza (IIT) kuyambika posachedwa ku US kufufuza 64Cu SAR-bisPSMA mu khansa ya prostate (NCT05286840)[1}.

Mlandu wotsogozedwa ndi ofufuza a X-Cancer wa SAR-bisPSMA mu khansa yodziwika bwino kapena yokayikira ya prostate (X-Calibur) ndi Gawo I/II IIT mwa odwala 150 ku Urology Cancer Center ndi GU Research Network (GURN) ku Omaha, Nebraska, mothandizidwa ndi Dr Luke Nordquist. Idzafufuza kuchuluka kwa odwala khansa ya prostate pojambula ndi 64Cu-SAR-bisPSMA pa tsiku la utsogoleri komanso panthawi ina. Mayesero a X-Calibur adzakhala akuwunika chitetezo cha 64Cu SAR-bisPSMA komanso kuyang'ana momwe mankhwalawa amakhudzira masitepe ndi kasamalidwe kachipatala kwa omwe ali ndi khansa ya prostate.

Wapampando wamkulu wa Clarity, Dr Alan Taylor, adati, "Ndife okondwa kuthandizira kuyesa kwa Dr Nordquist, yemwe adakumana ndi zogulitsa zathu mu mayeso a Theranostic 64Cu/67Cu SAR-bisPSMA SECuRE (NCT04868604) [2]. Tikuyembekeza kupitiliza kugwirira ntchito limodzi pakupititsa patsogolo chitukuko cha wothandizira wathu wa SAR-bisPSMA mu khansa ya prostate ndikuwunika maubwino ambiri a mankhwalawa monga gawo la pulogalamu ya Clarity's Targeted Copper Theranostics (TCT) pokwaniritsa cholinga chathu chowongolera chithandizo. zotsatira za odwala khansa. "

Khansara ya Prostate ndiyomwe imayang'ana kwambiri pulogalamu ya Clarity's Targeted Copper Theranostics (TCT), pomwe IIT ku GURN ndi mayeso achinayi azachipatala omwe amagwiritsa ntchito SAR-bisPSMA wothandizira pa khansa ya prostate. Theranostic 64Cu/67Cu SAR-bisPSMA yochokera ku US kuyesa, SECuRE (NCT04868604) [2], yatha kufanizira bwino odwala omwe ali ndi khansa ya prostate yosamva metastatic castrate kuyambira ola limodzi mpaka maola 1 atatha kubayidwa. Kuyesa kwa matenda a 72Cu SAR-bisPSMA ku Australia, PROPELLER (NCT64) [04839367], kuli mkati, ndipo opitilira 3% mwa omwe adatenga nawo gawo adalembedwa odwala omwe sanalandire chithandizo, omwe adatsimikizira odwala khansa ya prostate (ie pre-radical prostatectomy). Mayesero aposachedwa kwambiri a 50Cu SAR-bisPSMA ku US, COBRA (NCT64) [05249127], adalandira kalata ya Study May Proceed Letter kuchokera ku FDA mu February 4, ndikulemba anthu omwe ali ndi biochemical kuyambiranso kwa khansa ya prostate yomwe ikuyembekezeka kuyamba mu gawo lachiwiri la 2022. Clarity adalandirapo kale uphungu kuchokera ku FDA kuti pulogalamu yake ya prostate diagnostic clinic ndi 2022Cu SAR-bisPSMA ikuyankhula ndi anthu awiri oyenerera odwala kuti alembetse: pre-prostatectomy / pre-definitive treatment komanso odwala omwe akuganiziridwa kuti biochemical ayambiranso. .